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We correlated outpatient antibiotic use with prevalence
of penicillin-nonsusceptible Streptococcus pneumoniae
(PNSP), macrolide-resistant S. pneumoniae (MRSP), and
macrolide-resistant S. pyogenes (MRGAS) in 20 countries.
Total antibiotic use was correlated with PNSP (r = 0.75; p <
0.001), as was macrolide use with MRSP (r = 0.88; p <
0.001) and MRGAS (r = 0.71; p = 0.004). Streptococcal
resistance is directly associated with antibiotic selection
pressure on a national level.
A
global trend of increasing antimicrobial resistance,
but with wide variations at national levels, is well-
documented in the literature (1). Strong evidence supports
an association between antibiotic use and resistance in hos-
pitals (2,3). By contrast, the relationship between antibiot-
ic consumption and resistance has been more difficult to
establish for the outpatient setting, although some data
suggest a direct correlation for streptococcal infections
(4–6). For instance, an ecologic study linked penicillin-
nonsusceptibility in Streptococcus pneumoniae with β-lac-
tam and macrolide use in 12 European countries (7).
Recently, McCormick et al. have shown that variation in
pneumococcal resistance in the United States is best
explained by geographic variation in antibiotic selection
pressure, rather than by clonal dynamics (8).
Penicillin-nonsusceptible  S. pneumoniae (PNSP) and
macrolide-resistant S. pneumoniae (MRSP) are markers of
resistance to antibiotics commonly used as first-line drugs
for respiratory tract infections. Although penicillin-resist-
ant  S. pyogenes has never been observed to date, the
increasing rates of macrolide-resistant group A streptococ-
ci (MRGAS) pose considerable clinical problems in many
countries (4). The aim of this ecologic study was to corre-
late outpatient antibiotic consumption with reported rates
of PNSP, MRSP, and MRGAS in 20 countries on three
continents.
The Study
An ecologic study design was used, which allows
measurement of the total (individual and group-level)
effect of antibiotic exposure on antimicrobial resistance in
streptococci (9). PNSP, MRSP, and MRGAS were chosen
as indicator organisms for those effects. National outpa-
tient antibiotic sales data were obtained from published
reports, provided by IMS Health Global Services, the
National Corporation of Swedish Pharmacies, the Danish
Medicines Agency, and the Institute of Public Health in
Slovenia (7,10–13). Data for the United States were
extracted from IMS data (10). Sales data for total antibiot-
ic use (anatomic therapeutic classification [ATC] group
J01) and macrolide use (ATC group J01F) were used to
express outpatient consumption in defined daily doses
(DDD) per 1,000 inhabitants per day, as recommended by
the World Health Organization (WHO) (14).
By using MEDLINE, we performed a systematic search
of national and international surveillance studies published
in English, French, or German that reported proportional
frequencies of PNSP, MRSP, and MRGAS for 1994 to
2000. Representative resistance data from those countries
were included for which antibiotic sales data were also
available (6,7,10,13,15–34). A time lag of 0 to 2 years
between antibiotic sales and ensuing antimicrobial resist-
ance data was considered acceptable for this study. For
three countries (Iceland, Finland, and Sweden), the lag
time between antibiotic sales data and resistance rates was
0. Studies limited to small geographic areas not represen-
tative of a given country and studies limited to particular
patient populations were excluded. Nonsusceptibility to
penicillin and macrolide resistance included intermediate
and high-level resistance.
The relationship between total outpatient antibiotic
consumption and rates of PNSP was analyzed for 20 coun-
tries (Australia, Austria, Belgium, Canada, Denmark,
Finland, France, Germany, Greece, Iceland, Ireland, Italy,
Luxembourg, Netherlands, Norway, Portugal, Spain,
Sweden, United Kingdom, and United States). We also cal-
culated relationships between macrolide use and MRSPfor
16 countries (Australia, Austria, Belgium, Denmark,
Finland, France, Germany, Greece, Ireland, Italy,
Netherlands, Portugal, Slovenia, Spain, Sweden, and
United Kingdom), and between macrolide use and
MRGAS for 14 countries (Australia, Austria, Belgium,
Finland, France, Germany, Greece, Italy, Netherlands,
Portugal, Slovenia, Spain, Sweden, and United Kingdom).
For these correlation analyses, we used two-tailed
Spearman coefficients (r) for nonparametric correlations.
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of Geneva Hospitals, Geneva, SwitzerlandTotal use of outpatient antibiotics varied from 9.0
DDD/1,000 inhabitants per day in the Netherlands to 36.5
DDD/1,000 inhabitants/day in France (Figure 1).
Macrolide use varied from 1.0 DDD/1,000 inhabitants/day
in Sweden to 6.0 DDD/1,000 inhabitants/day in France
(Figure 2A). Average prevalence of PNSP also showed
marked differences, as shown in Figure 1. It was lowest in
Scandinavian countries (1% in Norway, 2% in Denmark,
4% in Sweden) and the Netherlands (1%); of medium level
in Germany (7%), the United Kingdom (11%), Austria
(12%), Belgium, and Italy (both 13%); and high in
Portugal (29%), Greece (31%), United States (34%),
France (43%), and Spain (50%). Figure 2A illustrates the
prevalence of MRSP, which was low in Scandinavia and
the Netherlands (3%–5%), medium level in Germany and
Portugal (both 9%), and high in Belgium (43%), Spain
(36%), and France (53%). MRGAS were distributed in a
similar pattern (Figure 2B), with northern European coun-
tries showing low levels (0%–4%) and Greece, Italy, and
Spain demonstrating the highest levels (29%–38%). Total
antibiotic use and prevalence of PNSP were significantly
correlated (r = 0.75; p < 0.001; Figure 1), as were
macrolide use and prevalence of MRSP (r = 0.88; p <
0.001; Figure 2A) and macrolide use and prevalence of
MRGAS (r = 0.71; p = 0.004; Figure 2B).
Conclusions
This report correlates national outpatient data about
antibiotic use with prevalence of antibiotic-resistant S.
pneumoniae and S. pyogenes in Europe, North America,
and Australia. The ecologic study design chosen allowed
us to evaluate the effect of antibiotic consumption on
resistance rates on a national level. A strong relationship
was documented between total volume of antibiotic con-
sumption and prevalence of PNSP. An almost linear asso-
ciation existed between macrolide use and proportion of
MRSP, a biologically plausible finding that has previously
been documented on a smaller scale (6). Aweaker, but still
significant correlation was found for MRGAS.
We found large differences in resistance rates, even in
neighboring countries. A variety of factors are responsible
for this, but the selective pressure exerted by inappropri-
ately used antibiotics is likely the most important (35).
Indeed, volume of antibiotic use varies widely between
countries (12). In previous cross-country comparisons of
Germany, France, and the United States (5,30), we sug-
gested that socioeconomic, cultural, and behavioral deter-
minants have a major impact on outpatient antibiotic
prescribing practices and resistance prevalence in respira-
tory pathogens on a national level. In addition, healthcare
policies play an important role. In Denmark, for instance,
an excessive use of tetracycline was noted, mainly for res-
piratory tract infections. This situation was corrected by
removing subsidization for tetracycline, which resulted in
a decrease in its use; this decrease was followed by a par-
allel decrease in tetracycline resistance among S. pneumo-
niae and other streptococci (36).
Antibiotic use exerts selective pressure on resistance in
respiratory pathogens in several ways (35). Any type of
recent antibiotic treatment (not only β-lactam agents) can
select PNSPby inhibiting susceptible commensal flora and
eradicating penicillin-susceptible pneumococci, thereby
indirectly promoting the transmission of PNSP and
increasing the prevalence of PNSP in a community or
country (9). However, whether decreasing antibiotic use in
the community will have a sustained impact on resistance
rates is unclear. Antibiotic resistance may take longer to
return to previous levels than the time it took for antibiot-
ic resistance to increase after excessive antibiotic use. In
Finland in the 1990s antibiotic resistance decreased slow-
ly with substantially reduced antibiotic consumption after
an initial rapid increase; such situations may lead to differ-
ent correlations between use and resistance, depending on
whether resistance is rising or falling (32).
This ecologic study has some limitations. First, antibi-
otic sales data cannot be used synonymously with antibiot-
ic exposure without highlighting the problem of patient
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Figure 1. Total antibiotic use in the outpatient setting (vertical axis)
versus prevalence of penicillin-nonsusceptible Streptococcus
pneumoniae (horizontal axis) in 20 industrialized countries. A
regression line was fitted with 95% confidence bands (r = 0.75; p
< 0.001).compliance, which is very difficult to quantify. However,
in case of low compliance, antibiotics may be used later,
and this self-medication may also contribute to resistance.
Second, large variations in resistance are typically found,
depending on the examined age group, with highest resist-
ance rates and largest amounts of antibiotic consumption
usually in children. Due to the study design chosen, we
could not account for these differences. Third, no single
surveillance study was identified that provided sufficient
data on national resistance rates for all countries.
Therefore, considerable heterogeneity was found among
the quality and characteristics of the included surveillance
studies. We tried to minimize this bias by excluding publi-
cations not meeting certain standards or examining only
selected patient populations. Fourth, the type and number
of tested organisms varied widely. Thus, sampling bias
may have influenced the results of this study. Finally, data
are lacking regarding the maximum time lag between
antibiotic consumption in the community and possible
changes in resistance patterns on a national level. Aperiod
of 1 to 2 years seems plausible, although more rapid
changes can be observed.
Further studies should be undertaken to extend our
analyses to Asian countries that are demonstrating high
rates of streptococcal resistance (31). Moreover, monitor-
ing of antimicrobial resistance should be continued on both
the regional and national level. An important role may be
played by networks such as the European Antimicrobial
Resistance Surveillance System. At the same time, disclo-
sure of sales data through pharmaceutical records may help
facilitate research in this area. In summary, the data pre-
sented in this ecologic analysis suggest an important asso-
ciation between antibiotic consumption and resistance in
streptococcal infections and lend support to the validity of
efforts by professional organizations and policymakers to
discourage overuse of antibiotics in the community.
Dr. Albrich is a fellow in infectious diseases at Emory
University School of Medicine, Atlanta, Georgia. His interests
include the epidemiology of antimicrobial-resistant pathogens
and sociocultural determinants of antibiotic overuse.
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